Emerging medical therapies for severe alcoholic hepatitis

키워드

참고문헌 (84)

1. Szabo G, "Alcohol-related liver disease: areas of consensus, unmet needs and opportunities for further study", Hepatology, 69, pp.2271~2283 (2019)
2. Mathurin P, "Management of alcoholic hepatitis", J Hepatol 2012;56 Suppl, 56(Suppl 1), pp.S39~S45 (2012)
3. Lucey MR, "Alcoholic hepatitis", N Engl J Med, 360, pp.2758~2769 (2009)
4. Szabo G, "Gut-liver axis and sterile signals in the development of alcoholic liver disease", Alcohol Alcohol, 52, pp.414~424 (2017)
5. Saha B, "Biomarkers of macrophage activation and immune danger signals predict clinical outcomes in alcoholic hepatitis", Hepatology, 70, pp.1134~1149 (2019)
6. Petrasek J, "IL-1receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice", J Clin Invest, 122, pp.3476~3489 (2012)
7. Bresnihan B, "Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist", Arthritis Rheum, 41, pp.2196~2204 (1998)
8. Alten R, "The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis", Arthritis Res Ther, 10, pp.R67~ (2008)
9. Ridker PM, "Antiinflammatory therapy with canakinumab for atherosclerotic disease", N Engl J Med, 377, pp.1119~1131 (2017)
10. Lachmann HJ, "Use of canakinumab in the cryopyrinassociated periodic syndrome", N Engl J Med, 360, pp.2416~2425 (2009)
11. Schroder K, "The inflammasomes", Cell, 140, pp.821~832 (2010)
12. Verma VK, "Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles", J Hepatol, 64, pp.651~660 (2016)
13. Pockros PJ, "Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C", Hepatology, 46, pp.324~329 (2007)
14. Frenette CT, "Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo", Clin Gastroenterol Hepatol, 17, pp.774~783.e4 (2019)
15. Harrison SA, "A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis", J Hepatol, 72, pp.816~827 (2020)
16. Wu D, "Alcohol, oxidative stress, and free radical damage", Alcohol Res Health, 27, pp.277~284 (2003)
17. Das SK, "Alcohol-induced oxidative stress", Life Sci, 81, pp.177~187 (2007)
18. Smilkstein MJ, "Efficacy of oral Nacetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study(1976 to 1985)", N Engl J Med, 319, pp.1557~1562 (1988)
19. Moreno C, "Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis : a randomized multicenter controlled trial", J Hepatol, 53, pp.1117~1122 (2010)
20. Stewart S, "A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis", J Hepatol, 47, pp.277~283 (2007)
21. Phillips M, "Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial", J Hepatol, 44, pp.784~790 (2006)
22. Nguyen-Khac E, "Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis", N Engl J Med, 365, pp.1781~1789 (2011)
23. Addolorato G, "Metadoxine in the treatment of acute and chronic alcoholism : a review", Int J Immunopathol Pharmacol, 16, pp.207~214 (2003)
24. Shpilenya LS, "Metadoxine in acute alcohol intoxication : a double-blind, randomized, placebo-controlled study", Alcohol Clin Exp Res, 26, pp.340~346 (2002)
25. Higuera-de la Tijera F, "Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis", Ann Hepatol, 13, pp.343~352 (2014)
26. Higuera-de la Tijera F, "Metadoxine improves the three-and six-month survival rates in patients with severe alcoholic hepatitis", World J Gastroenterol, 21, pp.4975~4985 (2015)
27. Anstee QM, "S-adenosylmethionine(SAMe)therapy in liver disease : a review of current evidence and clinical utility", J Hepatol, 57, pp.1097~1109 (2012)
28. Kim MJ, "DUR-928, an endogenous regulatory molecule, exhibits anti-inflammatory and antifibrotic activity in a mouse model of NASH", Emerging Trends Conference: Emerging Trends in Non alcoholic Fatty Liver Disease (2017)
29. Hassanein T, "Safety and efficacy of DUR-928: a potential new therapy for acute alcoholic hepatitis", Late-breaking oral presentation at AASLD’s The Liver Meeting (2019)
30. Michalopoulos GK, "Liver regeneration", J Cell Physiol, 213, pp.286~300 (2007)
31. Lin S, "Distributed hepatocytes expressing telomerase repopulate the liver in homeostasis and injury", Nature, 556, pp.244~248 (2018)
32. Piscaglia AC, "Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats", Gastroenterology, 133, pp.619~631 (2007)
33. Spahr L, "Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis : a randomized trial", Hepatology, 48, pp.221~229 (2008)
34. Garg V, "Granulocyte colony-stimulating factor mobilizes CD34(+)cells and improves survival of patients with acute-on-chronic liver failure", Gastroenterology, 142, pp.505~512.e1 (2012)
35. Kedarisetty CK, "Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis", Gastroenterology, 148, pp.1362~1370.e7 (2015)
36. Singh V, "Granulocyte colony-stimulating factor in severe alcoholic hepatitis : a randomized pilot study", Am J Gastroenterol, 109, pp.1417~1423 (2014)
37. Shasthry SM, "Efficacy of granulocyte colony-stimulating factor in the management of steroidnonresponsive severe alcoholic hepatitis : a double-blind randomized controlled trial", Hepatology, 70, pp.802~811 (2019)
38. Khawar MB, "How does interleukin-22 mediate liver regeneration and prevent injury and fibrosis?", J Immunol Res, 2016, pp.2148129~ (2016)
39. Pellicciari R, "6alpha-ethyl-chenodeoxycholic acid(6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity", J Med Chem, 45, pp.3569~3572 (2002)
40. Xu JY, "Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease", World J Gastroenterol, 20, pp.13493~13500 (2014)
41. Wu W, "Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease", Biochem Biophys Res Commun, 443, pp.68~73 (2014)
42. Verbeke L, "Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats", Hepatology, 59, pp.2286~2298 (2014)
43. Fiorucci S, "The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis", Gastroenterology, 127, pp.1497~1512 (2004)
44. Fiorucci S, "Cross-talk between farnesoid-X-receptor(FXR)and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis", J Pharmacol Exp Ther, 315, pp.58~68 (2005)
45. Peeraphatdit TB, "Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis", J Hepatol, 69, pp.275~277 (2018)
46. Bode JC, "Jejunal microflora in patients with chronic alcohol abuse", Hepatogastroenterology, 31, pp.30~34 (1984)
47. Yan AW, "Enteric dysbiosis associated with a mouse model of alcoholic liver disease", Hepatology, 53, pp.96~105 (2011)
48. Yan AW, "Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease", World J Hepatol, 4, pp.110~118 (2012)
49. Llopis M, "Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease", Gut, 65, pp.830~839 (2016)
50. Flamm SL, "Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence", Therap Adv Gastroenterol, 4, pp.199~206 (2011)
51. Döhler JR, "Bovine colostrum in oral treatment of enterogenic endotoxaemia in rats", Crit Care, 6, pp.536~539 (2002)
52. Han Sung Choi, "Bovine Colostrum Prevents Bacterial Translocation in an Intestinal Ischemia", Reperfusion-Injured Rat Model, 2009, pp.12(1), 37~46[DOI]
53. Ohashi W, "Contribution of zinc and zinc transporters in the pathogenesis of inflammatory bowel diseases", J Immunol Res, 2019, pp.8396878~ (2019)
54. Wang Y, "Lactobacillus rhamnosus GG reduces hepatic TNFα production and inflammation in chronic alcohol-induced liver injury", J Nutr Biochem, 24, pp.1609~1615 (2013)
55. Kirpich IA, "Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury : a pilot study", Alcohol, 42, pp.675~682 (2008)
56. Stadlbauer V, "Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis", J Hepatol, 48, pp.945~951 (2008)
57. Han SH, "Effects of probiotics(cultured Lactobacillus subtilis", Streptococcus faecium)in the treatment of alcoholic hepatitis : randomized-controlled multicenter study, 2015, pp.27, 1300~1306
58. Philips CA, "Healthy donor fecal microbiota transplantation in steroidineligible severe alcoholic hepatitis : a pilot study", Clin Gastroenterol Hepatol, 15, pp.600~602 (2017)
59. Philips CA, "Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis", Indian J Gastroenterol, 37, pp.215~225 (2018)
60. Duan Y, "Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease", Nature, 575, pp.505~511 (2019)
61. Sipeki N, "Immune dysfunction in cirrhosis", World J Gastroenterol, 20, pp.2564~2577 (2014)
62. Louvet A, "Infection in patients with severe alcoholic hepatitis treated with steroids : early response to therapy is the key factor", Gastroenterology, 137, pp.541~548 (2009)
63. Sanyal AJ, "A randomized, prospective, double-blind, placebocontrolled trial of terlipressin for type 1 hepatorenal syndrome", Gastroenterology, 134, pp.1360~1368 (2008)
64. Martín-Llahí M, "Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome : a randomized study", Gastroenterology, 134, pp.1352~1359 (2008)
65. Neri S, "Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome", Dig Dis Sci, 53, pp.830~835 (2008)
66. Markwick LJ, "Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis", Gastroenterology, 148, pp.590~602 (2015)
67. Thompson J, "Extracorporeal cellular therapy(ELAD)in severe alcoholic hepatitis : a multinational, prospective, controlled, randomized trial", Liver Transpl, 24, pp.380~393 (2018)
68. Iracheta-Vellve A, "Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice", J Hepatol, 63, pp.1147~1155 (2015)
69. Bala S, "Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases", Hepatology, 56, pp.1946~1957 (2012)
70. Lippai D, "Micro-RNA-155deficiency prevents alcohol-induced serum endotoxin increase and small bowel inflammation in mice", Alcohol Clin Exp Res, 38, pp.2217~2224 (2014)
71. Babuta M, "Dysregulated autophagy and lysosome function are linked to exosome production by micro-RNA 155 in alcoholic liver disease", Hepatology, 70, pp.2123~2141 (2019)
72. Tornai D, "Inhibition of triggering receptor expressed on myeloid cells 1 ameliorates inflammation and macrophage and neutrophil activation in alcoholic liver disease in mice", Hepatol Commun, 3, pp.99~115 (2018)
73. Ambade A, "Pharmacological inhibition of CCR2", 5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice, 2019, pp.69, 1105~1121
74. Thursz MR, "Prednisolone or pentoxifylline for alcoholic hepatitis", N Engl J Med, 373, pp.282~283 (2015)
75. Naveau S, "A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis", Hepatology, 39, pp.1390~1397 (2004)
76. Boetticher NC, "A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis", Gastroenterology, 135, pp.1953~1960 (2008)
77. Trinchet JC, "Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial", Gastroenterol Clin Biol, 13, pp.551~555 (1989)
78. Morgan TR, "Colchicine treatment of alcoholic cirrhosis : a randomized, placebo-controlled clinical trial of patient survival", Gastroenterology, 128, pp.882~890 (2005)
79. Bird GL, "Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis", J Hepatol, 28, pp.194~198 (1998)
80. Bird G, "Insulin and glucagon infusion in acute alcoholic hepatitis : a prospective randomized controlled trial", Hepatology, 14, pp.1097~1101 (1991)
81. Trinchet JC, "Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon : a multicenter sequential trial", Hepatology, 15, pp.76~81 (1992)
82. Fede G, "Propylthiouracil for alcoholic liver disease", Cochrane Database Syst Rev, 2011, pp.CD002800~ (2011)
83. "Oral abstracts (abstracts 1–299)", Hepatology, 68(Suppl 1), pp.1~183 (2018)
84. Rambaldi A, "Anabolic-androgenic steroids for alcoholic liver disease", Cochrane Database Syst Rev, (1), pp.CD003045~ (2003)

관련 논문AI추천